Cargando…
Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk
HIV incidence continues to be unacceptably high in Eastern and Southern Africa, with women disproportionately affected. An increased per-contact risk of HIV acquisition among African, Caribbean, and other Black (ACB) women has been associated with the higher prevalence of bacterial vaginosis (BV) in...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665571/ https://www.ncbi.nlm.nih.gov/pubmed/34893070 http://dx.doi.org/10.1186/s40168-021-01183-x |
_version_ | 1784614036560674816 |
---|---|
author | Armstrong, Eric Kaul, Rupert |
author_facet | Armstrong, Eric Kaul, Rupert |
author_sort | Armstrong, Eric |
collection | PubMed |
description | HIV incidence continues to be unacceptably high in Eastern and Southern Africa, with women disproportionately affected. An increased per-contact risk of HIV acquisition among African, Caribbean, and other Black (ACB) women has been associated with the higher prevalence of bacterial vaginosis (BV) in these communities, wherein the vaginal microbiota is predominated by diverse pro-inflammatory anaerobic bacteria. However, while the vaginal microbiota in BV-free women is typically predominated by one of several different Lactobacillus spp., the degree of HIV protection afforded by a Lactobacillus-predominant vaginal microbiota also varies considerably. Specifically, L. crispatus is associated with an immunoregulatory genital immune environment, exclusion of BV-associated bacteria, and reduced HIV risk. In contrast, less HIV protection or exclusion of BV-associated bacteria and fewer immune benefits have been associated with L. iners—which is unfortunately the most common Lactobacillus species among ACB women. These species-specific clinical differences are underpinned by substantial genomic differences between Lactobacillus species: for instance, the much smaller genome of L. iners lacks the coding sequence for D-lactic acid dehydrogenase and cannot produce the D-lactate isomer that enhances HIV trapping in mucus but encodes for epithelial cell toxins and stress resistance proteins that may enhance bacterial survival in the context of microbiota and environmental fluctuations. While more studies are needed to elucidate whether differences in HIV protection between Lactobacillus species are due to direct genital immune effects or the exclusion of proinflammatory BV-associated bacteria, the current body of work suggests that for BV treatment to succeed as an HIV prevention strategy, it may be necessary to induce a vaginal microbiota that is predominated by specific (non-iners) Lactobacillus species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01183-x. |
format | Online Article Text |
id | pubmed-8665571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86655712021-12-13 Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk Armstrong, Eric Kaul, Rupert Microbiome Review HIV incidence continues to be unacceptably high in Eastern and Southern Africa, with women disproportionately affected. An increased per-contact risk of HIV acquisition among African, Caribbean, and other Black (ACB) women has been associated with the higher prevalence of bacterial vaginosis (BV) in these communities, wherein the vaginal microbiota is predominated by diverse pro-inflammatory anaerobic bacteria. However, while the vaginal microbiota in BV-free women is typically predominated by one of several different Lactobacillus spp., the degree of HIV protection afforded by a Lactobacillus-predominant vaginal microbiota also varies considerably. Specifically, L. crispatus is associated with an immunoregulatory genital immune environment, exclusion of BV-associated bacteria, and reduced HIV risk. In contrast, less HIV protection or exclusion of BV-associated bacteria and fewer immune benefits have been associated with L. iners—which is unfortunately the most common Lactobacillus species among ACB women. These species-specific clinical differences are underpinned by substantial genomic differences between Lactobacillus species: for instance, the much smaller genome of L. iners lacks the coding sequence for D-lactic acid dehydrogenase and cannot produce the D-lactate isomer that enhances HIV trapping in mucus but encodes for epithelial cell toxins and stress resistance proteins that may enhance bacterial survival in the context of microbiota and environmental fluctuations. While more studies are needed to elucidate whether differences in HIV protection between Lactobacillus species are due to direct genital immune effects or the exclusion of proinflammatory BV-associated bacteria, the current body of work suggests that for BV treatment to succeed as an HIV prevention strategy, it may be necessary to induce a vaginal microbiota that is predominated by specific (non-iners) Lactobacillus species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01183-x. BioMed Central 2021-12-10 /pmc/articles/PMC8665571/ /pubmed/34893070 http://dx.doi.org/10.1186/s40168-021-01183-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Armstrong, Eric Kaul, Rupert Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk |
title | Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk |
title_full | Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk |
title_fullStr | Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk |
title_full_unstemmed | Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk |
title_short | Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk |
title_sort | beyond bacterial vaginosis: vaginal lactobacilli and hiv risk |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665571/ https://www.ncbi.nlm.nih.gov/pubmed/34893070 http://dx.doi.org/10.1186/s40168-021-01183-x |
work_keys_str_mv | AT armstrongeric beyondbacterialvaginosisvaginallactobacilliandhivrisk AT kaulrupert beyondbacterialvaginosisvaginallactobacilliandhivrisk |